NIOX GroupCSSPF 77 Days Payable is 40.34 as of Dec. 2025, which is 82% below its 10-year median of 221.55. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, NIOX Group ranks worse than 76.23% on this metric.
NIOX Group's average Accounts Payable for the
six
months ended in Dec. 2025 was $2.22 Mil. NIOX Group's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $10.04 Mil.
Hence, NIOX Group's Days Payable for the
six
months ended in Dec. 2025 was 40.34.
The historical rank and industry rank for NIOX Group's Days Payable or its related term are showing as below:
CSSPF'
s Days Payable Range Over the Past 10 Years
Min: 20.05 Med: 221.55 Max: 857.13
Current: 39.74
During the past 13 years, NIOX Group's highest Days Payable was 857.13. The lowest was 20.05. And the median was 221.55.
CSSPF's Days Payable is ranked worse than 76.23% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs CSSPF: 39.74
NIOX Group's Days Payable
increased
from Dec. 2024 (39.42) to Dec. 2025 (40.34).
It may suggest that NIOX Groupdelayed paying its suppliers.
NIOX Group Days Payable Related Terms
NIOX Group Days Payable Historical Data
* Premium members only.
The historical data trend for NIOX Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Days Payable distribution charts can be found below:
* The bar in red indicates where NIOX Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
NIOX Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Days Payable of 40.34 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NIOX Group and its competitors. This is 82% below median its historical median of 221.55. Over the past decade, NIOX Group's Days Payable has ranged from 20.05 to 857.13. According to the industry distribution chart, NIOX Group ranks #606 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 76.2%.
Is NIOX Group's Days Payable too high?
NIOX Group's current Days Payable of 40.34 is 82% below median its 10-year median of 221.55. Over the past 10 years, this metric has ranged from a low of 20.05 to a high of 857.13. The Medical Devices & Instruments industry median Days Payable is 67.87. NIOX Group's value of 40.34 is 40.6% below this industry median. Based on the distribution chart, NIOX Group ranks #606 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #606 out of 795 companies for Days Payable. This places NIOX Group in the lower half of its industry. The industry median Days Payable is 67.87. NIOX Group's value of 40.34 is 40.6% below this benchmark. Historically, NIOX Group's own Days Payable has ranged from 20.05 to 857.13 over the past decade. While the company's 10-year median is 221.55 vs. the industry median of 67.87, NIOX Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Days Payable of 40.34 is 40.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Days Payable is 40.34, which is 82% below median its own 10-year median of 221.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current Days Payable is 40.34, which is 82% below median its 10-year median of 221.55 and 40.6% below the Medical Devices & Instruments industry median of 67.87. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Days Payable is 40.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Days Payable: 40.34 (82% below median its 10-year median of 221.55)
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
Industry Position: 40.6% below the Medical Devices & Instruments median (#606 of 795)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
